NDA 203684 · Bracco
Lumason
Sulfur Hexafluoride Lipid-Type A Microspheres · Intravenous · Contrast Agent for Ultrasound Imaging
NovelLast checked: Nov 20, 2026Latest source record: Apr 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Oct 10, 2014
Approved uses
4
Original approval plus efficacy supplements
Registered trials
27
7 Phase 3, 7 recruiting
FAERS reports
1,980
1,360 serious, 101 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions ( 5.1 )] . Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions ( 5.1 )] . Assess all patients for the presence of any condition that precludes administration [see Contraindications ( 4 )] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions ( 5.1 )] . WARNING: SERIOUS CARDIOPULMONARY REACTIONS See full prescribing information for complete boxed warning Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride...
What it is approved for
From the label in effect Sep 9, 2026.
Echocardiography Lumason is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. Ultrasonography of the Liver Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions. Ultrasonography of the Urinary Tract Lumason is indicated for use in ultrasonography of the urinary tract in pediatric patients for the evaluation of suspected or known vesicoureteral reflux. Lumason is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms ( 1 ) in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients ( 1 ) in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients ( 1 )
Mechanism: Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues. For ultrasonography of the urinary tract in pediatric patients, the intravesically administered Lumason microspheres increase signal intensity of fluids within the urethra, bladder, ureters, and renal pelvis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2019 Supplement 5 · Efficacy LabelLetterPediatric Medical Review
- Dec 22, 2016 Supplement 2 · Efficacy · priority review LabelLetter
- Mar 31, 2016 Supplement 1 · Efficacy LabelLetter
- Oct 10, 2014 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPediatric Medical Review
1 products under this application
- LUMASON · SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES 60.7MG/25MG · FOR SUSPENSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sulfur Hexafluoride Lipid A Microspheres" as an intervention, any sponsor and status, largest first.
- Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver TumorsRecruiting
john eisenbreyAcademic, hospital or other
NCT06261814 · 266 participants (planned) · Start Aug 7, 2024 · Primary completion Jul 1, 2027
Drug: Sulfur Hexafluoride Lipid Microspheres · For: Liver Neoplasms
Sites: Philadelphia, Pennsylvania
john eisenbreyAcademic, hospital or other
NCT05641935 · 210 participants (planned) · Start Nov 3, 2022 · Primary completion Aug 31, 2027
Drug: Sulfur Hexafluoride Lipid Microspheres · For: Recurrent Renal Cell Carcinoma; Renal Cell Carcinoma
Sites: Philadelphia, Pennsylvania
- Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141Pivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT02522481 · 175 participants · Start Sep 24, 2015 · Primary completion Nov 7, 2017
Drug: Lumason · For: Coronary Artery Disease
Sites: Tucson, Arizona; La Jolla, California; West Hills, California · 17 sites in all
- Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142Pivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT02552238 · 174 participants · Start Oct 12, 2015 · Primary completion Jun 22, 2017
Drug: Lumason · For: Coronary Artery Disease
Sites: Santa Ana, California; Wilmington, Delaware; Homestead, Florida · 13 sites in all
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT03490929 · 146 participants (planned) · Start Jun 1, 2018 · Primary completion Dec 31, 2026
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON] · For: Trauma Abdomen
Sites: Rochester, Minnesota; Philadelphia, Pennsylvania
- Lumason® Infusion vs. Bolus AdministrationsPivotal-lookingRecruiting
Bracco Diagnostics, IncIndustry
NCT06400004 · 106 participants (planned) · Start Jul 10, 2024 · Primary completion Aug 29, 2026
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]; Lumason · For: Heart Diseases
Sites: West Hills, California; Atlanta, Georgia; Boston, Massachusetts · 6 sites in all
University of Southern CaliforniaAcademic, hospital or other
NCT06171607 · 100 participants (planned) · Start Nov 5, 2020 · Primary completion Nov 5, 2026
Drug: Perflutren Lipid Microspheres; Sulfur Hexafluoride Lipid Microspheres · For: Breast Carcinoma
Sites: Los Angeles, California · 2 sites in all
- Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)Not yet recruiting
Boston Children's HospitalAcademic, hospital or other
NCT03653702 · 70 participants (planned) · Start Jul 1, 2027 · Primary completion Jun 2029
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] · For: Vesico-Ureteral Reflux
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea335
- nausea277
- anaphylactic reaction252
- hyperhidrosis231
- flushing196
- hypotension168
- dizziness162
- feeling hot157
- hypersensitivity136
- erythema135
- blood pressure decreased125
- unresponsive to stimuli123
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 17 |
| 2013 | 9 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 22 |
| 2017 | 34 |
| 2018 | 60 |
| 2019 | 69 |
| 2020 | 72 |
| 2021 | 129 |
| 2022 | 215 |
| 2023 | 448 |
| 2024 | 280 |
| 2025 | 277 |
| 2026 | 346 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Lumason (Sulfur Hexafluoride Microsphr) · HCPCS Q9950
2024 spending
$314K
Beneficiaries
3,798
4,038 claims
Per beneficiary
$83
2024 ASP limit $18.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $511,720 |
| 2021 | $243,089 |
| 2022 | $323,440 |
| 2023 | $323,788 |
| 2024 | $313,880 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Use of lumason/sonovue in contrast-enhanced ultrasound of the kidney for characterization of renal masses-a meta-analysis.
Barr RG · Abdom Radiol (NY) 2022 · Meta-Analysis, Review
- Comparative Safety of Ultrasound Enhancing Agents: A Systematic Review and Bayesian Network Meta-Analysis.
Gonzalez RF, Cabra A, Liu D, et al. · Am J Cardiol 2025 · Systematic Review, Comparative Study
- Contrast-Enhanced Ultrasound Compared With Hepatobiliary Agent MRI for Differentiation of Focal Nodular Hyperplasia and Hepatic Adenoma: A Prospective Trial.
Swensson J, McCrate M, Halappa VG, et al. · Ultrasound Q 2024 · Comparative Study, Clinical Trial
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.